Currently, there are 3.38B common shares owned by the public and among those 3.34B shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 33 analysts who have offered their price forecasts for NVO have a consensus price objective of $148.37. The analysts have set the share’s price value over the next 12 months at a high of $175.81 and a low of $83.55. The average price target is 16.63% above its recent price level and a downside to the estimated low will see the stock lose -48.06% over that period. But an upside of 29.64% will see the stock hit the forecast high price target while median target price for the stock is $156.10.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of -9.64% and -13.06% over the past three months. NVO shares are trading 19.57% year to date (YTD), with the 12-month market performance up to 35.50% higher. It has a 12-month low price of $86.96 and touched a high of $148.15 over the same period. NVO has an average intraday trading volume of 3.86 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.87%, -7.12%, and -1.83% respectively.
Institutional ownership of Novo Nordisk ADR (NYSE: NVO) shares accounts for 10.07% of the company’s 3.38B shares outstanding.
It has a market capitalization of $412.96B and a beta (3y monthly) value of 0.43. The stock’s trailing 12-month PE ratio is 42.46, while the earnings-per-share (ttm) stands at $2.91. The company has a PEG of 15.16 and a Quick Ratio of 0.75 with the debt-to-equity ratio at 0.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.96% over the week and 1.64% over the month.
Analysts forecast that Novo Nordisk ADR (NVO) will achieve an EPS of 0.91 for the current quarter, 0.94 for the next quarter and 4.35 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.84 while analysts give the company a high EPS estimate of 0.84. Comparatively, EPS for the current quarter was 0.73 a year ago. Earnings per share for the fiscal year are expected to increase by 24.65%, and 26.42% over the next financial year. EPS should shrink at an annualized rate of 2.80% over the next five years, compared to 16.48% over the past 5-year period.
Looking at the support for the NVO, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on May 30, 2024, with the firm’s price target at $156. BMO Capital Markets coverage for the Novo Nordisk ADR (NVO) stock in a research note released on April 12, 2024 offered a Outperform rating with a price target of $163. Cantor Fitzgerald on their part issued Overweight rating on December 01, 2023.
